Search results
Results from the WOW.Com Content Network
In February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID-19.
On 9 February 2021, the FDA issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in people twelve years of age or older weighing at least 40 kilograms (88 lb) who test positive for SARS‑CoV‑2 and who are at high risk for progressing to severe COVID ...
Russia commits to deliver the first doses of Gamaleya's Sputnik V COVID-19 vaccine to the Philippines around April 2021. The Philippines and Russia are also negotiating regarding a plan to set up a production facility for Sputnik V vaccines in the Philippines. [124] The first batch of Gamaleya's vaccine, consisting of 15,000 doses, arrived on ...
In January 2021, the United States agreed to purchase 1.25 million doses of the drug for $2.625 billion, at $2,100 per dose. [29] [30] On 14 September, another 1.4 million doses were purchased for the same price, totaling $2.94 billion. [31] In January 2021, the German government purchased 200,000 doses for €400 million at €2,000 per dose. [32]
Vaccine combinations (few exceptions), antibiotics, low-dose steroids (less than 20 mg per day), minor infections with low fever (below 38.5º Celsius), diarrhea, malnutrition, kidney or liver disease, heart or lung disease, non-progressive encephalopathy, well controlled epilepsy or advanced age, are not contraindications to vaccination.
[2] [16] The CBC report in late April 2021 also stated that "it could be eligible for a slice of $113 million in additional funding from the National Research Council of Canada Industrial Research Assistance Program". The federal government had provided funding to some other companies in Canada that were also working to develop a COVID-19 vaccine.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate
Of the 1,453 preterm infants in the trial, 969 received a single dose of nirsevimab and 484 received placebo. [15] Among infants who were treated with nirsevimab, 25 (2.6%) experienced MA RSV LRTI compared with 46 (9.5%) infants who received placebo. [15] nirsevimab reduced the risk of MA RSV LRTI by approximately 70% relative to placebo. [15]